Genostim Performance Labs
Strategic Sales Initiative
Channel Architecture · Distribution Strategy · Revenue Forecast · Advisory for Equity
Prepared by Pet Jet LLC Advisory Consortium · April 2026 · CONFIDENTIAL
At a Glance
The Initiative in Four Numbers
5
Distribution Channels
Sequentially activated across 36 months
$38M
Year-3 Revenue Target
Base case annual run rate
20%
Equity Stake Offered
15–20% range; no upfront fees
M14
Cash Breakeven
Projected Month 14–16 cumulative
Chapter 1
Executive Summary
This Strategic Sales Initiative converts 20 years of peptide research into a multi-channel revenue engine. It covers five distribution channels, a quarterly revenue build, a 36-month financial model, and the Advisory for Equity engagement structure — delivering the full program without upfront advisory fees.
The Science Edge
The Isotide™/Hexatide™ Complex — 18 amino acids, 21 growth factors, pinocytosis delivery — supports ten documented benefit pillars across human and companion animal applications.
The Proposal
Pet Jet LLC Advisory Consortium offers a 15–20% equity stake in exchange for full sales infrastructure, channel development, technology, and financial advisory. No fees. Equity only.
Executive Summary
The Scale of the Opportunity
$3.2B
Serviceable Addressable Market (SAM)
$110M
Year-5 Stretch Revenue Target
$66M
Consortium Equity Value at Year 5 (20% stake)
The consortium succeeds when Genostim succeeds. This alignment is the foundation of the entire engagement.
Chapter 2 · Market Dynamics
Human Peptide Supplement Market
$717M → $1.156B
Market size 2023 to 2033, ~7% CAGR (broader functional peptide market at 18%)
3–5× Spending Premium
Biohacker and longevity consumers spend far more per year than average supplement buyers
Peptide Literacy at All-Time High
'Peptide therapy' searches tripled 2021–2024; GLP-1, BPC-157, and growth factor media coverage drives awareness. GRAS designation enables DTC sale without FDA approval.
Market Dynamics
Pet Supplement Market
$4.76B Market, ~10% CAGR
One of the fastest-growing categories in pet care (2025)
Pet Humanization Premium
Millennial/Gen Z owners spend 40% more per pet than prior generations; vet-recommended products command 2–3× price premium vs. mass retail
TGFL White Space
No peptide/growth factor pet supplement competitor has credible clinical documentation. Chewy autoship reached 82% of net sales by Q3 2024 — subscription models dominate.
Market Dynamics
The Dual-Brand Household Advantage
The dual-brand architecture — Genostim® for humans and TGFL® for pets — creates a unique household penetration model. A subscriber using both products represents $840–1,200/year in annual revenue at full autoship, with acquisition cost amortized across two product lines.
No competitor in either category has this cross-species platform. 66% of US households own a pet; among premium supplement buyers, pet ownership exceeds 70%.
Household Revenue Potential
Single brand: $720–1,080/yr
Dual autoship: $840–1,200/yr
Acquisition cost: shared across both brands
Chapter 3 · Revenue Forecast
3-Year Channel Revenue Build
Revenue builds from $3.1M in Year 1 to $11.8M in Year 2 to $38.0M in Year 3, driven by sequential channel activation and compounding autoship subscriber growth.
Revenue Forecast
Channel Targets at a Glance
Chapter 4 · Quarterly Forecast
Q1 2026 → Q2 2028: 10-Quarter Build
Total revenue grows from $120K in Q1 2026 to $11.8M/quarter by Q2 2028 — an annualized rate of $43M, consistent with the Year 3 base case.
Quarterly Forecast · Key Inflection Points
When Each Channel Reaches Critical Mass
1
Q1 2026
DTC launch only; $120K total revenue
2
Q3 2026
Affiliate network passes 100 active partners; vet/retail activates materially
3
Q1 2027
All 5 channels active; $2.3M quarter; autoship base established
4
Q2 2028
$11.8M quarter; $43M annualized run rate
Chapter 5 · Channel Playbooks
Five Channels, One Revenue Engine
Channels are activated sequentially to manage working capital and operational complexity, with each layer compounding the revenue base established before it.
Channel 1
DTC / E-Commerce
The DTC channel is the business's most valuable long-term asset — direct customer relationships, full margin retention, and first-party data. The autoship program is the key economic flywheel: at 45% autoship rate and $90 AOV/month, a base of 10,000 subscribers generates $9.7M/year in predictable revenue.
Shopify Rebuild
Mobile-first, science-storytelling UX, quiz funnel for personalized recommendations
Amazon FBA
5 priority SKUs, Brand Registry, A+ content, Subscribe & Save enrollment
Email/SMS
50,000-person list target by Month 12; 30-day onboarding sequence
Loyalty Program
Tiered rewards for autoship subscribers — drives LTV and reduces churn
Channel 2
Affiliate Marketing & Influencer Programs
Affiliate marketing is the most capital-efficient customer acquisition channel for a supplement brand with differentiated science. The Crockett Peptide Effect research provides affiliate content creators with source material no competitor can match.
Affiliate Networks
ShareASale / Impact / CJ — 20% recurring commission (Thorne standard), 60-day cookie
Micro-Influencers
Tier 1 (50K–500K): sports recovery, anti-aging, pet health niches; 200 ambassadors in Month 1
Podcast Advertising
Longevity/biohacking shows (Huberman Lab, Lifespan, Ben Greenfield) — CPM model
Target
200+ active affiliates by Month 12; $0.8M Year 1 affiliate-attributed revenue
Channel 3
Veterinary Clinics & Pet Specialty Retail
The veterinary channel is the most defensible distribution pathway for TGFL. A vet-recommended product commands a 2–3× price premium vs. mass retail, generates the highest LTV customer, and creates an educational relationship that drives ongoing multi-product recommendations.
MWI Animal Health
National vet distributor; 25,000+ clinic relationships; priority onboarding
Patterson Veterinary
Second largest vet distributor; complementary geographic coverage
Covetrus
Practice management + product distribution integration; TGFL catalog integration
Vet CE Portal
4-module online course: pinocytosis, growth factors, companion animal applications
Channel 3 · Pet Specialty Retail
Retail Partners for TGFL
Retail Strategy
Enter markets where slotting fees are low or absent, demonstrate shelf velocity, then use that data to negotiate favorable terms with higher-volume retailers in Year 2–3.
- Natural Grocers — no slotting fees, science-values merchandising, 168 locations
- Whole Foods Market — premium positioning, independent pet stores
- CrossFit affiliates and functional fitness facilities — direct shelf placement, community trust
Vet Clinic Display Kit
Counter display, QR-linked science library, and sample program — designed to drive practitioner confidence and patient recommendation at the point of care.
Channel 4
Specialty Natural & Traditional Retail
Retail shelf presence is a credibility signal that reinforces DTC and veterinary sales. The strategy enters low-slotting-fee markets first, builds velocity data, then scales to higher-volume retailers.
01
Natural Grocers by Vitamin Cottage
No slotting fees; science-values merchandising; 168 locations — Year 1 entry point
02
Vitamin Shoppe
700+ locations; category buyer focus on emerging peptide/adaptogen segment
03
GNC
2,200 locations; slotting fee $150–500/SKU/store; Year 2–3 target
04
Independent Health Food Stores
Broker-managed via UNFI or KeHE distribution networks
Channel 5
International Export
GRAS designation provides a strong regulatory foundation for international expansion. One preferred distributor per geography is the recommended channel model.
Canada
Health Canada Natural Health Product license (NPN) — GRAS basis simplifies application
EU
EFSA-compliant structure/function claims; German and UK natural retail channels priority
Australia
TGA listed medicine pathway; Chemist Warehouse and pharmacy channel distribution
Singapore / Japan
Premium DTC + retailer partnerships; strong premium wellness market; longer-term opportunity
Chapter 6 · Dual-Brand Strategy
The Dual-Brand Household Strategy
The same household that contains a health-conscious adult and a companion animal is the target customer for both brands. A Genostim subscriber who also has a dog or cat represents $120–180/month in potential dual-brand autoship value — acquired with a single marketing touch.
Dual-Brand Strategy
Household LTV: The Economic Case
$2,400
Human+Pet LTV
Dual autoship, 80% 12-month retention (vs. $720–1,080 single-brand)
+110%
LTV Uplift
Incremental per household via dual-brand conversion
35%
Cross-Sell Target
25–35% of single-brand subscribers convert dual within 6 months
$160
Dual-Brand AOV
$140–160/order at full autoship vs. $80–90 single-brand
66% of US households own a pet. Among premium supplement buyers, pet ownership exceeds 70% — the cross-sell opportunity is structurally embedded in the customer base.
Dual-Brand Strategy
A Category-Creating Position
"The same growth factor science that supports your performance also supports your pet's health."
No competitor in either the human peptide or pet supplement space has a credible, science-backed equivalent in the adjacent market. Genostim is the only company that can make this claim — and that is a category-creating position.
Genostim®
Human performance, longevity, and recovery — 18 amino acids, 21 growth factors
TGFL®
Companion animal health — same pinocytosis delivery science, no credible competitor
Chapter 7 · Financial Model
36-Month Financial Model
$27K
Month 1 Revenue
Initial DTC/affiliate only
$260K
Month 12 Revenue
5 channels active, autoship base established
$980K
Month 24 Revenue
National retail, vet distribution, international pipeline
$3.2M
Month 36 Revenue
$38M annual run rate
The 36-month base case projects cumulative revenue of approximately $53M over three years, reflecting compounding subscriber accumulation, channel diversification, and organic traffic growth.
36-Month Financial Model
Unit Economics & Cost Structure
Margin & COGS
55% Gross Margin
Premium DTC supplement standard
COGS Breakdown
Manufacturing 28% / Packaging 8% / Fulfillment 9% / Returns 10%
Operating Model
Marketing Spend
35% of revenue Year 1 → 18% Year 3 as organic efficiency compounds
Fixed OpEx
$80K/month (team + technology + G&A)
36-Month Financial Model
Investment & Cash Position
$500,000
Initial investment — co-investment supported by consortium
Month 14–16
Projected cash breakeven on a cumulative basis
~$8.4M
3-year net cash positive at end of Month 36
The model reaches cash breakeven by Month 14–16 and generates approximately $8.4M in net positive cash by the end of Year 3 — without requiring additional capital raises beyond the initial $500K.
Chapter 8 · Advisory for Equity
Advisory for Equity — Engagement Structure
The Advisory for Equity structure aligns the consortium's long-term incentives with Genostim's commercial success and eliminates the working capital drain of traditional advisory fees. The consortium provides its full service scope in exchange for an equity position. Cash is preserved for product, marketing, and channel development.
Advisory for Equity
Why Equity Over Commission?
Commission Model
Incentivizes transaction volume but not business quality. Optimizes for next month's sales number — not long-term brand value or defensible distribution.
Equity Model
Incentivizes the consortium to build sustainable infrastructure, establish defensible distribution, and develop the brand asset that drives valuation. The consortium is a co-founder of Genostim's commercial success, not a vendor.
Advisory for Equity
Engagement Terms
Advisory for Equity
Equity Value Creation Path
At a conservative 3× revenue multiple, the consortium's equity stake grows from $4.7–6.2M at Year 1 to $49.5–66M at Year 5. Category brands typically trade at 4–8× revenue, suggesting meaningful upside to these projections.
Chapter 9 · Sales Operations
Sales Operations Infrastructure
Executing the five-channel strategy requires purpose-built infrastructure — CRM, order management, analytics, and fulfillment systems that scale from $3M to $100M without fundamental rebuilds. Scale Foundry and TIN provide this as part of the equity engagement.
Shopify Plus
DTC storefront, subscription management, wholesale portal (B2B2C)
Klaviyo
Email/SMS marketing automation; behavioral segmentation; lifecycle sequences
Northbeam / Triple Whale
Multi-touch attribution; channel-level ROAS tracking
Custom AI Platform (TIN)
SEO content generation, keyword monitoring, competitor intelligence
Sales Operations Infrastructure
Key Performance Indicators
Chapter 10 · Engagement Terms
Engagement Terms & Next Steps
The Pet Jet LLC Advisory Consortium is prepared to execute a term sheet and begin work upon agreement on equity terms.
Engagement Terms
Five Steps to Kickoff
01
Mutual NDA Execution
Pet Jet LLC ↔ Genostim Performance Labs — executed at first meeting
02
Data Room Preparation
Genostim prepares financials, customer data, COGS detail, and IP inventory
03
Consortium Due Diligence
2-week confidential process conducted by the consortium
04
Term Sheet Delivery & Negotiation
Equity terms, vesting schedule, and services scope finalized
05
LOI Execution → Phase 1 Kickoff
Letter of Intent signed; engagement commences; Phase 1 infrastructure build begins
The Consortium
Who Is Behind This Initiative?
Pet Jet LLC
Lead advisor and consortium coordinator; brand strategy, channel architecture, and engagement management
Scale Foundry
Sales operations infrastructure, technology stack deployment, and CRM/ERP implementation
The Information Network (TIN)
AI content platform, SEO infrastructure, keyword intelligence, and organic traffic growth
Velocity Partners International
International distribution, export channel development, and global regulatory navigation
Summary
Why This Initiative Wins
Differentiated Science
20 years of peptide research; Isotide™/Hexatide™ Complex with pinocytosis delivery — no commodity supplement
Dual-Brand Moat
The only company with credible science-backed products in both human peptide and pet supplement categories
5-Channel Architecture
Sequential activation manages risk while compounding revenue — from DTC to international export
Aligned Incentives
No fees. Equity only. The consortium's $49.5–66M Year-5 stake value is earned only when Genostim succeeds.
Ready to Build Something Exceptional
The Pet Jet LLC Advisory Consortium is prepared to execute a term sheet and begin work immediately upon agreement on equity terms.
Contact
joey@mypetjet.com · mypetjet.com
Date
April 2026
Classification
CLIENT PROPOSAL — CONFIDENTIAL · Not for distribution